



January 22, 2025

NEWS RELEASE

Company name: TMS Co., Ltd.
Name of representative: Takuro Wakabayashi, Chief Executive Officer
(Securities code: 4891; Growth4 Market)

Announcement of presentation on TMS-007(JX10) at International Stroke Conference (ISC) 2025

TMS Co., Ltd. (the "Company") is pleased to announce that Dr. Edmond Chen (MD), CMO, Cardiovascular at CORXEL Pharmaceuticals, will make a presentation on TMS-007 (JX10) at the International Stroke Congress2025 (ISC 2025), to be held from February 4th to 7th, 2025.

Results of the Phase 2a study of TMS-007 (JX10) conducted by the Company were recently published in *Stroke*¹, including an illustration of JX10's proposed mechanism on the cover of the December 2024 print version.

Details of Presentation at ISC 2025

Title : A Novel Thrombolytic with Anti-inflammatory Properties (JX10) Improves Neurological Outcomes in Acute Lacunar Infarct up to 12 hours After Onset
Presenter : Edmond Chen, M.D. – CMO, Cardiovascular at CORXEL Pharmaceuticals
Date : February 5, 2025
Session Title : Acute Treatment: Systemic Thrombolysis and Cerebroprotection, Oral Abstracts II
Session Time : 15:30-16:30 (Los Angeles local time)
Location : Los Angeles Convention Center, CA, USA
ISC2025 URL : <https://professional.heart.org/en/meetings/international-stroke-conference>

¹ Niizuma, Kuniyasu et al. Anti-Inflammatory Thrombolytic JX10 (TMS-007) in Late Presentation of Acute Ischemic Stroke. *Stroke*. 2024;55;12.
<https://doi.org/10.1161/STROKEAHA.124.048464>

About TMS Co., Ltd.

TMS Co., Ltd. is a clinical-stage biopharmaceutical company focused on the discovery and development of transformative medicines for the treatment of serious diseases in areas of high unmet medical need. The Company's pipeline consists of a family of small molecule compounds called SMTPs (Stachybotrys Microspora Triprenyl Phenols) derived from a fungus. TMS' lead program, TMS-007 (JX10), has demonstrated efficacy and safety in its Phase 2a study for the treatment of acute ischemic stroke. The Company's robust pipeline also includes programs in resistant or uncontrolled hypertension, acute kidney injury, and spinal cord injury. TMS continues to explore new pipeline products by leveraging its established partnerships with leading academic institutions in Japan, with the intention to build a bridge between academic discoveries and the global pharmaceutical market. For more information about TMS, please visit <https://www.tms-japan.co.jp/en/>

Investor and Media Contact:
ir@tms-japan.co.jp

End